ARTICLE | Clinical News
Aronex reports Phase II Atragen data in NHL
December 4, 2000 8:00 AM UTC
ARNX said that in an ongoing Phase II study of its Atragen injectable liposomal all-trans retinoic acid to treat relapsed or refractory non-Hodgkin's lymphoma (NHL) and cutaneous T cell lymphoma, 17 o...